These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 32915409)

  • 1. Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
    Lampertico P; Mauss S; Persico M; Barclay ST; Marx S; Lohmann K; Bondin M; Zhang Z; Marra F; Belperio PS; Wedemeyer H; Flamm S
    Adv Ther; 2020 Nov; 37(11):4755-4756. PubMed ID: 32915409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
    Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC
    Gastroenterol Hepatol (N Y); 2017 Dec; 13(12 Suppl 5):1-24. PubMed ID: 29950953
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
    Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ
    Int J Drug Policy; 2019 Apr; 66():73-79. PubMed ID: 30735896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
    Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
    Toyoda H; Atsukawa M; Watanabe T; Nakamuta M; Uojima H; Nozaki A; Takaguchi K; Fujioka S; Iio E; Shima T; Akahane T; Fukunishi S; Asano T; Michitaka K; Tsuji K; Abe H; Mikami S; Okubo H; Okubo T; Shimada N; Ishikawa T; Moriya A; Tani J; Morishita A; Ogawa C; Tachi Y; Ikeda H; Yamashita N; Yasuda S; Chuma M; Tsutsui A; Hiraoka A; Ikegami T; Genda T; Tsubota A; Masaki T; Tanaka Y; Iwakiri K; Kumada T
    J Gastroenterol Hepatol; 2020 May; 35(5):855-861. PubMed ID: 31609495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H
    J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world.
    Tamori A; Inoue K; Kagawa T; Takaguchi K; Nouso K; Iwasaki Y; Minami M; Hai H; Enomoto M; Kawada N
    Hepatol Res; 2019 Dec; 49(12):1365-1373. PubMed ID: 31323165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction to: Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis.
    Lu M; Rupp LB; Melkonian C; Trudeau S; Daida YG; Schmidt MA; Gordon SC
    Adv Ther; 2024 Jun; 41(6):2534-2535. PubMed ID: 38598114
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
    Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
    J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects.
    Kosloski MP; Zhao W; Li H; Pugatch D; Asatryan A; Kort J; Mensa FJ; Liu W
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):779-789. PubMed ID: 30861340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study.
    Morishita A; Ogawa C; Moriya A; Tani J; Yoneyama H; Fujita K; Oryu M; Senoo T; Takaguchi K; Masaki T
    Hepatol Res; 2020 May; 50(5):557-564. PubMed ID: 31883211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis.
    Wang X; Fan X; Deng H; Zhang X; Zhang K; Li N; Han Q; Lv Y; Liu Z
    Int J Antimicrob Agents; 2019 Dec; 54(6):780-789. PubMed ID: 31284039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
    Kosloski MP; Bow DAJ; Kikuchi R; Wang H; Kim EJ; Marsh K; Mensa F; Kort J; Liu W
    J Pharmacol Exp Ther; 2019 Aug; 370(2):278-287. PubMed ID: 31167814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study.
    Ogawa E; Furusyo N; Nakamuta M; Nomura H; Satoh T; Takahashi K; Koyanagi T; Kajiwara E; Dohmen K; Kawano A; Ooho A; Azuma K; Kato M; Shimoda S; Hayashi J;
    Hepatol Res; 2019 Jun; 49(6):617-626. PubMed ID: 30849206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    Suda G; Hasebe C; Abe M; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Haga H; Ueno Y; Abe K; Takahashi A; Ohira H; Tsukuda Y; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Inoue J; Terasita K; Ohara M; Kawagishi N; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jul; 54(7):641-649. PubMed ID: 30778716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of Glecaprevir/Pibrentasvir in the treatment of mixed cryo-globulinemia due to chronic hepatitis C cirrhosis in a patient with chronic kidney disease.
    Papadopoulos N; Flouda S; Sveroni E; Tatarida Palla MC; German V
    Hippokratia; 2019; 23(1):30-32. PubMed ID: 32256037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
    Bethea ED; Gaj K; Gustafson JL; Axtell A; Lebeis T; Schoenike M; Turvey K; Coglianese E; Thomas S; Newton-Cheh C; Ibrahim N; Carlson W; Ho JE; Shah R; Nayor M; Gift T; Shao S; Dugal A; Markmann J; Elias N; Yeh H; Andersson K; Pratt D; Bhan I; Safa K; Fishman J; Kotton C; Myoung P; Villavicencio MA; D'Alessandro D; Chung RT; Lewis GD
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):771-780. PubMed ID: 31353243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of glecaprevir and pibrentasvir combination therapy in old-aged patients with chronic hepatitis C virus infection.
    Watanabe S; Morimoto N; Miura K; Murohisa T; Tahara T; Sato T; Tano S; Fukaya Y; Kurata H; Okamura Y; Numao N; Uehara K; Murayama K; Nakazawa K; Sugaya H; Yoshizumi H; Iijima M; Tsukui M; Hirosawa T; Takaoka Y; Nomoto H; Maeda H; Goka R; Isoda N; Yamamoto H
    J Rural Med; 2020 Oct; 15(4):139-145. PubMed ID: 33033533
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.